Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
3.000
+0.160 (5.63%)
Mar 9, 2026, 2:04 PM EDT - Market open
Adagene Employees
Adagene had 138 employees as of December 31, 2024. The number of employees decreased by 36 or -20.69% compared to the previous year.
Employees
138
Change (1Y)
-36
Growth (1Y)
-20.69%
Revenue / Employee
$748
Profits / Employee
-$216,592
Market Cap
141.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 138 | -36 | -20.69% |
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | 198 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Sangamo Therapeutics | 183 |
| Artiva Biotherapeutics | 106 |
| Connect Biopharma Holdings | 62 |
| Spero Therapeutics | 32 |
| Cardiff Oncology | 31 |
| Unicycive Therapeutics | 23 |
ADAG News
- 20 days ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Adagene Provides Business Update and 2026 Objectives - GlobeNewsWire
- 2 months ago - Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) - GlobeNewsWire
- 4 months ago - Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - GlobeNewsWire
- 4 months ago - Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 6 months ago - Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - GlobeNewsWire
- 6 months ago - Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - GlobeNewsWire
- 6 months ago - Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - GlobeNewsWire